Granted Patent
B2
US 7,214,684 · App. 10/989,514 · Granted May 8, 2007
Methods for the treatment of allergic rhinitis
Assignee:
Sepracor Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Claims (2)
1. A method of treating allergic rhinitis in a human comprising orally administering to a human a therapeutically effective amount of descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof, wherein the amount of the descarboethoxyloratadine administered is 0.1 mg to 5 mg per day.
2. The method of claim 1 , wherein the amount of said descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof, is administered together with a pharmaceutically acceptable carrier.
Assignments (2)
CHANGE OF NAME
Recorded Jan 25, 2011
From: SEPRACOR INC.
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 025689/0743 →
CHANGE OF NAME
Recorded Nov 24, 2010
From: SEPRACOR INC.
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 025521/0941 →
Continuity (5)